The current drug price system is so opaque that it is easy to see why there are many questions about PBM motives and practices.
The Prescription Pricing for the People bill requires the FTC to study pharmaceutical intermediaries, including vertical...
In the Grassley-Wyden 2-year investigation into insulin price-gouging, we found that that PBM scheme encourages drug mak...
The Pharmacy Benefit Manager (PBM) Transparency Act (S. 127) requires transparency reporting by PBMs to shine sunlight o...
Prohibits deceptive, unfair pricing schemes, including spread pricing and arbitrary clawbacks of payments made to pharma...
This bill puts sunshine on PBMs and saves taxpayers $740 million.
I believe it is our duty to understand how the pharmaceutical supply chain is working, and what we can do to improve it.